|
|
Philips Research Press Release
|
Philips and Bruker BioSpin sign memorandum of understanding to bring new imaging technology to the preclinical market
|
|
Montreal, Canada
- At the 2009 World Molecular Imaging Congress
(WMIC) in Montreal, Royal Philips Electronics (NYSE:
PHG, AEX: PHI) and Bruker BioSpin, a division of
Bruker Corporation (NASDAQ: BRKR), today announced
that they have signed a memorandum of understanding
(MOU) for the development of Magnetic Particle
Imaging (MPI) scanners, a new imaging technology,
for the preclinical market. The partnership would
unite Philips’ strength in medical imaging and
Bruker BioSpin’s leadership in analytical magnetic
resonance instruments and preclinical Magnetic
Resonance Imaging (MRI).
Under the terms of the MOU, Bruker BioSpin intends to develop and
manufacture the preclinical MPI scanner at its
facilities in Ettlingen, Germany. Both parties
intend to co-market the resulting solution.
Preclinical imaging has emerged as a powerful tool
in disease studies, translational research and drug
discovery. Philips and Bruker BioSpin believe that
the addition of MPI as a complementary preclinical
imaging technique has great potential to help
researchers gain new insights in disease processes
at the organ, cellular and molecular level.
MPI is a new medical imaging technology developed by
scientists at Philips. It uses the magnetic
properties of iron-oxide nanoparticles to produce
three-dimensional images of the concentration of
nanoparticles injected into the bloodstream. The
potential of the technology for medical and
industrial research and, ultimately, patient care,
was demonstrated in a publication which appeared in
the March issue of Physics in Medicine and Biology
in 2009 (Volume 54, issue 5). It was shown that MPI
technology can be used to produce real-time images
that accurately capture the activity in the
cardiovascular system of a mouse.
“We are very pleased about this collaboration with
Philips on this exciting technology. Magnetic
Particle Imaging is expected to allow scientists to
explore an extensive range of new imaging
capabilities and applications in preclinical
research, ” said Wulf-Ingo Jung, Managing Director
of Bruker BioSpin MRI GmbH. “The highly sensitive
visualization of functional characteristics in vivo
at high temporal resolution bears great potential
for small animal imaging, especially when combined
with high spatial resolution morphological MRI.”
“Through its combined speed, resolution and
sensitivity, our Magnetic Particle Imaging
technology has great potential for the diagnosis,
therapy planning and therapy response assessment for
major diseases such as heart disease and cancer,”
said Diego Olego, Senior Vice President and Chief
Technology Officer of Philips Healthcare. “We are
excited about the agreement with Bruker BioSpin as
it will lead to the availability of MPI scanners for
preclinical research studies, which is a
prerequisite for establishing the value of this
promising new technology for patient care.”

Philips Research has developed a new medical imaging
technology called Magnetic Particle Imaging (MPI). The
depicted prototype of the preclinical MPI scanner was
developed as part of the MAGIC (Magnetic Particle Imaging
for Cardio-Vascular Applications) research project. The
project was funded by the German Federal Ministry of
Education and Research as part of the NanoForLife Framework
Program.
|
A key success factor for the effective translation
of new imaging concepts into practice are
partnerships with leading academic medical
institutions, industrial partners and governments.
Bringing together such partnerships is one of the
underlying principles behind Philips’ policy of open
innovation. The results obtained in the MAGIC
(Magnetic Particle Imaging for Cardio-Vascular
Applications) research project conducted at the
Philips Research Laboratories in Hamburg (Germany),
have significantly contributed to the development of
MPI. The project was funded by the German Federal
Ministry of Education and Research under grant
Number 13N9079 as part of the NanoForLife Framework
Program. The project was started in 2006 and will
finish by the end of this year.
For further information, please contact:
|
|
| Philips
Steve Klink
Communications Department Philips Research
Tel.: +31 40 27 43703
Mobile: +31 6 10888824
E-mail: steve.klink@philips.com
|
Bruker BioSpin
Dr. Thorsten Thiel,
Director Marketing Communications
Bruker BioSpin
Tel.: +49 721 5161 6517
E-mail: thorsten.thiel@bruker.de
|
About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a
diversified Health and Well-being company, focused on improving people’s lives
through timely innovations. As a world leader in healthcare, lifestyle and
lighting, Philips integrates technologies and design into people-centric
solutions, based on fundamental customer insights and the brand promise of
“sense and simplicity”. Headquartered in the Netherlands, Philips employs more
than 118,000 employees in more than 60 countries worldwide. With sales of EUR 26
billion in 2008, the company is a market leader in cardiac care, acute care and
home healthcare, energy efficient lighting solutions and new lighting
applications, as well as lifestyle products for personal well-being and pleasure
with strong leadership positions in flat TV, male shaving and grooming, portable
entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.
|
About Bruker BioSpin
For more information about Bruker BioSpin and Bruker
Corporation, please visit
www.bruker-biospin.com and
www.bruker.com.
Bruker cautionary statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future
results to differ materially from current expectations
include, but are not limited to, risks and uncertainties
relating to adverse changes in conditions in the global
economy and volatility in the capital markets, the
integration of businesses we have acquired or may acquire in
the future, changing technologies, product development and
market acceptance of our products, the cost and pricing of
our products, manufacturing, competition, dependence on
collaborative partners and key suppliers, capital spending
and government funding policies, changes in governmental
regulations, intellectual property rights, litigation, and
exposure to foreign currency fluctuations. These and other
factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our
annual report on Form 10-K for the year ended December 31,
2008, our most recent quarterly reports on Form 10-Q and our
current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements other
than as required by law.
|
|
|
|
|